The study is evaluating the safety and effectiveness of Viekira Pak to treat pediatric patients with chronic hepatitis C genotypes 1 and 4.  Viekira Pak is already approved by the Food and Drug Administration to treat adults with hepatitis C.  This is the first clinical trial of Viekira Pak to treat pediatric patients.

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects (ZIRCON)

To view the entire clinical trial description, click here

 

Share This Page
Follow Us